Investor Presentaiton

Investor presentation ADA 2019 Novo Nordisk is investigating opportunities within NASH Semaglutide NASH phase 2 programme 2016 2017 2018 2019 2020 Semaglutide 0.1, 0.2 and 0.4 mg QD vs placebo in patients with NASH ~320 patients, 72 weeks Semaglutide 0.4 mg QD vs placebo in patients with NASH ~70 patients, 72 weeks Slide 27 Proof of concept phase 2 combination trial design 100 NAFLD/NASH MRI-PDFF with > 10% steatosis FibroScan with liver stiffness ≥ 7 kPa or historical liver biopsy Sema 2.4 mg once weekly sc Sema 2.4 mg + FIR 20 mg once daily oral Sema 2.4 mg + CIL 30 mg once daily oral Sema 2.4 mg + CIL 100 mg once daily oral Sema 2.4 mg + FIR 20 mg + CIL 30 mg 24 weeks + 7 weeks follow-up Semaglutide 2.4 mg QW vs placebo in patients with NASH ~70 patients, 48 weeks Expected phase 2 programme completion: H2 2020 Trial information • Safety and tolerability trial Initiation Q3 2019 • MRI-PDFF, MRE & biomarkers at least at: 0, 12, 24 weeks QD: Once-daily; QW: once-weekly; sc: subcutaneous; MRI-PDFF: magnetic resonance imaging-estimated proton density fat fraction; MRE: magnetic resonance elastography; NASH: nonalcoholic steatohepatitis; NAFLD: Nonalcoholic fatty liver disease; kPa: kilopascals; FIR: firsocostat (ACC inhibitor); CIL: cilofexor (FXR agonist); ACC: acetyl-CoA carboxylase; FXR: Farnesoid X receptor novo nordisk

View entire presentation